PMGC's NorthStrive Expands IP Portfolio into Human Muscle Preservation for GLP-1 Market
Event summary
- NorthStrive Biosciences filed two new U.S. patent applications (Nos. 19/709,895 and 19/709,950) targeting muscle preservation in GLP-1 and obesity treatment markets.
- Applications cover EL-22 and EL-32 for preserving lean muscle mass during weight loss treatments, including GLP-1 receptor agonists and dual/triple agonist therapies.
- Patents include combination approaches with apelin or ursolic acid, and multiple delivery forms (oral, injectable, nasal, topical).
- Expansion from animal health to human pharmaceutical applications, addressing sarcopenia, obesity-related weight loss, and neurogenic atrophy.
The big picture
The filings represent a strategic pivot from animal health to human pharmaceuticals, targeting a growing need for muscle preservation in the GLP-1 and obesity treatment markets. This move aligns with the rapid adoption of weight loss therapies like semaglutide and tirzepatide, where maintaining lean muscle mass is becoming increasingly important. The expansion of the EL-22 and EL-32 IP portfolio positions PMGC to capitalize on this emerging segment within the broader obesity treatment landscape.
What we're watching
- Market Adoption
- How quickly EL-22 and EL-32 can gain traction in the competitive GLP-1 and obesity treatment markets.
- Regulatory Approval
- The pace at which NorthStrive can secure regulatory approvals for human-use applications of EL-22 and EL-32.
- Competitive Positioning
- Whether NorthStrive can differentiate its muscle preservation solutions from existing and emerging therapies.